… rationale for how dapagliflozin may reduce complications in patients who are hospitalized
… This definition is consistent with Kidney Disease Improving Global Outcomes–defined stage …

… Short-term cost impact of dapagliflozin in chronic kidney disease. Poster presentation at
the National Kidney Foundation (NKF) 2023 Spring Clinical Meeting, April 11–15, Austin, TX. …

… empagliflozin, canagliflozin and dapagliflozin reduce the risk of HF and slow kidney disease
progression in patients with T2DM at cardiovascular risk or with established cardiovascular …

… in dapagliflozin-treated patients … patients with a broad range of underlying kidney diseases,
we cannot generalize our results to patients with type 1 diabetes, polycystic kidney disease, …

… Dapagliflozin (DAPA), a sodium-glucose transporter 2 inhibitor (SGLT2i), attenuates kidney
outcomes in patients with not only diabetes mellitus (DM) but also chronic kidney disease (…

… With acknowledgment that race is a social construct, Black and White patients appeared
to experience similar kidney and cardiovascular benefits of dapagliflozin in this study. …

… We examined the effects of dapagliflozin on the primary end point, a composite of
sustained decline in eGFR of ≥50%, end-stage kidney disease, or death from kidney or …

… , it is most likely that both organs contribute significantly to dapagliflozin metabolism. Importantly,
the impact of chronic kidney disease on the liver metabolism of dapagliflozin is currently …

… of CV death, HHF, and kidney outcomes, and have a consistent benefits for CV death/HHF
and progression of kidney disease with dapagliflozin. Patients with PAD had a higher risk of …

… The study included patients with chronic kidney disease (CKD) and the possibility of using
dapagliflozin at a dose of 10 mg once a day compared with placebo. The study involved 386 …